The Peter Marks effect
The pharma industry, Wall Street and former government officials on Monday decried the forced resignation of FDA vaccine ...
Fierce Pharma1d
For struggling cell and gene therapy field, Peter Marks' FDA exit adds even more uncertainty
The sudden resignation of Peter Marks, M.D., Ph.D., from the FDA branch that regulates biological products for humans ...
Who Is Dr. Peter Marks? FDA’s Top Vaccine Official Quits, Citing RFK Jr.’s ‘Misinformation And Lies.’
Marks offered his resignation while citing Kennedy’s “misinformation and lies” and an “unprecedented assault on scientific ...
STAT2d
Marks’ exit is not exactly helping industry sentiment
Vaccine makers were hit particularly hard yesterday, as Marks’ resignation letter alluded to disagreements with HHS Secretary ...
Marks’ Resignation Is a ‘Blow for Biotech Industry,’ Says RBC Analyst as Biotech Stocks Fall
Biotech stocks took a hit after the sudden resignation of Dr. Peter Marks, head of the FDA’s Center for Biologics Evaluation ...
Fierce Pharma3d
As FDA's Peter Marks resigns, industry watchers size up vaccine, cell and gene therapy hits
As the FDA wavers from cuts, changes and departures under the second Trump administration, another vital figure of the agency ...
US FDA insider Steele replaces Marks as top vaccine official, for now
The U.S. Food and Drug Administration said on Tuesday it had named Scott Steele as acting director of its Center for ...
Dr. Peter Marks, top vaccine official at FDA, resigns and criticizes RFK Jr.
Dr. Peter Marks, the top vaccine official at the Food and Drug Administration, wrote in a letter that he was resigning from ...
MedCity News1d
Ouster of Peter Marks & Mass FDA Layoffs Have Biotech Sector Bracing for Regulatory Disruptions
As the FDA’s top biologics official, Peter Marks oversaw regulation of cell and gene therapies. The departure of Marks and mass layoffs throughout the FDA raise concerns about the agency’s ability to ...
BioPharma Dive3d
Cell, gene therapy makers lose a champion at FDA with exit of Peter Marks
Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.
BioSpace3d
Marks’ Sudden Departure From FDA Magnifies Uncertainty, Sends Biopharma Shares Down
The stock market—and biotech insiders—reacted negatively to the allegedly forced resignation of CBER Director Peter Marks, ...